---
title: "Huachuang Securities Keeps Their Buy Rating on Lepu Biopharma Co. Ltd. Class H (2157)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282435919.md"
description: "In a report released yesterday, from Huachuang Securities maintained a Buy rating on Lepu Biopharma Co. Ltd. Class H, with a price target of HK$8.10.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Lepu Biopharma Co. Ltd. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$8.10."
datetime: "2026-04-12T06:25:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282435919.md)
  - [en](https://longbridge.com/en/news/282435919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282435919.md)
---

# Huachuang Securities Keeps Their Buy Rating on Lepu Biopharma Co. Ltd. Class H (2157)

In a report released yesterday, from Huachuang Securities maintained a Buy rating on Lepu Biopharma Co. Ltd. Class H, with a price target of HK$8.10.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Lepu Biopharma Co. Ltd. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$8.10.

### Related Stocks

- [02157.HK](https://longbridge.com/en/quote/02157.HK.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Lepu Biopharma Signals 2025 Profit on Strong Oncology Sales and Licensing Gains](https://longbridge.com/en/news/278629108.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Sensorion Appoints Fred Chereau as Chief Executive Officer](https://longbridge.com/en/news/286719182.md)